trial

A Study Measuring Effect of LY2140023 (Pomaglumetad Methionil) on Electrocardiographs in Participants With Schizophrenia

NCTId NCT01606436
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 86 (actual)
Sponsored by Denovo Biopharma LLC
Primary completion 2012-08
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
86 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Double
Start
2012-06
Primary completion
2012-08
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
PomaglumetadMoxifloxacin

Sponsors

Denovo Biopharma LLCLead Sponsor

Investigators

1
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)Study Director

Sites

8 total
Garden Grove, United StatesSan Diego, United StatesNorth Miami, United StatesOverland Park, United StatesRockville, United StatesSt Louis, United StatesPhiladelphia, United StatesAustin, United States

Facts & assertions

4 sourced
Enrollment
86
Phase
PHASE1
Primary Completion Date
2012-08
Status
COMPLETED
relationships
The graph out of here
drug
Pomaglumetad
drug
Moxifloxacin
drug
lead_sponsor
Denovo Biopharma LLC
company
indication
Schizophrenic Disorders
indication
Schizophrenia
indication
investigator
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)
person